Contact Us

Opening hours: Monday to Friday: 8:00am to 5:00pm, Saturday: 8:30am to 12:30pm

What You Should Know About Tuberculosis

Tuberculosis (TB) is caused by a bacteria called Mycobacterium TuberculosisAlthough TB is contagious, it is not easily contracted.

This disease normally attack the lungs, but it may also affect different part of your body such as kidneys, spine or brain.

An interesting fact about TB is, adults are more prone to this disease than children. 

This is because adults on average have more contact with other adults.

Signs & Symptoms of Tuberculosis

Signs & symptoms of Tuberculosis includes:

  • Coughing for more than 3 weeks
  • Fever
  • Fatigue
  • Loss of appetite
  • Night sweats

Additionally, people with a weakened immune system are at risk of getting tuberculosis disease. These are typically people with these conditions:

  • HIV infection
  • Diabetes mellitus
  • Low body weight
  • Organ transplants
  • Substance use

Treatment of Tuberculosis

Like many other diseases, TB is treatable by using a combination of drugs.

The treatment period may take six to twelve months. 

The choice of drugs, as well as duration of treatment, is dependent on the severity of TB.

However, it is important that you comply with your medications. Skipping doses or medications may cause the bacteria to mutate, causing the disease to be deadlier and harder to treat. 

Prevention against Tuberculosis

Last but not least, prevention is always better than cure. 

The BCG (Bacille Calmette-Guerin) vaccination may help against TB. It is a live vaccine from weakened Mycobacterium Bovis.

Above all, a healthy immune system is the best prevention from TB.

It is also important to help stop the spread of TB. With this in mind, if you are infected with TB, you should stay home, ventilate the room and always wear a mask.

Mayflax is a provider for various medications. You can get various drugs at a reasonable price from us for your clinics or hospitals. Contact us here to know more!

REFERENCES

TB antibiotics in reaching targets

Cr. Simone van der Koelen

Source from Sciencedaily.com

Researchers have built up another technique that empowers them to envision how well antibiotics against tuberculosis (TB) reach at their pathogenic targets inside human hosts. The discoveries, published in the journal Science, boost understanding of how antibiotics work and could help direct the development of new antibiotics, which are truly necessary in the fight against drug-resistance.

TB treatment

TB stays as one of the world’s deadliest infectious diseases, with over a million TB-related deaths worldwide every year.

At the point when an individual is infected with Mtb (mycobacteria), their immune system attempts to clear the microorganism by calling upon specialised immune cells called as macrophages that perceive and engulf Mtb. However, the bacteria frequently discover ways to survive and duplicate, causing illness. Patients require at least four antibiotics for at six months to defeat the disease.

It was previously unknown whether antibiotics enter all the compartments of the macrophage where the Mtb hide and duplicate.

The method pioneered in this study, which consolidates three kinds of imaging (correlated light, electron and nano-scale ion microscopy), permits researchers to picture the circulation of TB drugs in Mtb-infected human macrophages at high resolution, for the first time.

A test-case TB drug

Utilizing bedaquiline as an test-case, the group contaminated human macrophages with Mtb, and following up after two days, they treated them with the medication. Their imaging results revealed that bedaquiline accumulated in various compartments of the cell, most eminently, inside lipid droplets.

The bacteria can interact with and consume these lipid droplets. Be that as it may, the group (Crick-led team) didn’t know whether bedaquiline would be moved to the bacteria, or whether the lipid droplets were retaining the antibiotic and keeping it from arriving at the bacteria. Including a chemical that kept lipid droplets from forming significantly decreased the measure of bedaquiline in Mtb, proposing that the lipid drops are responsible for moving antibiotic to the bacteria.

“Now that we can see exactly where antibiotics go once they enter macrophages, we can build up a much clearer picture of how they reach their targets, and harness these observations to design more effective treatments in the future, not only for TB but for other infectious diseases too” says Max Gutierrez, Crick group leader and senior author of the paper.

Share the post!